Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

CPhI South Korea

Korea positioned to be global biopharma powerhouse, says industry association

Stem cells and biosimilars are driving the Korean pharma market, according to the country’s Biomedicine Industry Association KoBIA.

update - Hospira regrets non-compliance

Pfizer unit Hospira and Napp broke APBI code during Remsima push

Pfizer’s Hospira unit and Napp Pharmaceuticals broke ABPI rules covering the promotion of biosimilar medicines according to the UK industry group.

CPhI South Korea 2016

Accelerating timelines vital to securing slice of biosimilars market, KBI

Accelerated development gives biosimilars an upper hand in gaining market share, CMO KBI Biopharma told delegates in Korea yesterday.

Fast-tracked Factor Xa inhibitor is being made for Portola by CMC Biologics and Lonza

Portola 'surprised' with CMC concerns in FDA rejection of anticoagulant candidate

Portola Pharmaceuticals says it was "caught off guard" after the US FDA raised manufacturing concerns in a complete response letter for its Factor Xa inhibitor, AndexXa.

Cost pressures turning pharma towards automation tech, says Zenith

Increased cost pressures and a shift to biologics manufacturing are driving demand for automation technologies, says Zenith which is opening two offices in the US.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...